These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease. Xu S; Chan P Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626 [TBL] [Abstract][Full Text] [Related]
47. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy. Fernández-Valle T; Gabilondo I; Gómez-Esteban JC Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931 [TBL] [Abstract][Full Text] [Related]
48. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Simonsen AH; Kuiperij B; El-Agnaf OM; Engelborghs S; Herukka SK; Parnetti L; Rektorova I; Vanmechelen E; Kapaki E; Verbeek M; Mollenhauer B Biomark Med; 2016; 10(1):19-34. PubMed ID: 26314196 [TBL] [Abstract][Full Text] [Related]
49. In vivo gastric detection of α-synuclein inclusions in Parkinson's disease. Sánchez-Ferro Á; Rábano A; Catalán MJ; Rodríguez-Valcárcel FC; Fernández Díez S; Herreros-Rodríguez J; García-Cobos E; Álvarez-Santullano MM; López-Manzanares L; Mosqueira AJ; Vela Desojo L; López-Lozano JJ; López-Valdés E; Sánchez-Sánchez R; Molina-Arjona JA Mov Disord; 2015 Apr; 30(4):517-24. PubMed ID: 25113060 [TBL] [Abstract][Full Text] [Related]
50. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease. Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897 [TBL] [Abstract][Full Text] [Related]
52. A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson's disease. Pouclet H; Lebouvier T; Coron E; Des Varannes SB; Neunlist M; Derkinderen P Neurogastroenterol Motil; 2012 Apr; 24(4):e202-5. PubMed ID: 22292943 [TBL] [Abstract][Full Text] [Related]
53. Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review. Bougea A; Koros C; Stefanis L J Neural Transm (Vienna); 2019 Nov; 126(11):1373-1382. PubMed ID: 31401695 [TBL] [Abstract][Full Text] [Related]
54. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Gelpi E; Navarro-Otano J; Tolosa E; Gaig C; Compta Y; Rey MJ; Martí MJ; Hernández I; Valldeoriola F; Reñé R; Ribalta T Mov Disord; 2014 Jul; 29(8):1010-8. PubMed ID: 24395122 [TBL] [Abstract][Full Text] [Related]
55. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Braak H; Sandmann-Keil D; Gai W; Braak E Neurosci Lett; 1999 Apr; 265(1):67-9. PubMed ID: 10327208 [TBL] [Abstract][Full Text] [Related]
56. Glutathione Jewett M; Dickson E; Brolin K; Negrini M; Jimenez-Ferrer I; Swanberg M Front Neurol; 2018; 9():222. PubMed ID: 29681884 [TBL] [Abstract][Full Text] [Related]
57. Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease. Grassi D; Howard S; Zhou M; Diaz-Perez N; Urban NT; Guerrero-Given D; Kamasawa N; Volpicelli-Daley LA; LoGrasso P; Lasmézas CI Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2634-E2643. PubMed ID: 29487216 [TBL] [Abstract][Full Text] [Related]